Cookie preferences
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
Track device being used
Item number | Size | Datasheet | Manual | SDS | Delivery time | Quantity | Price |
---|---|---|---|---|---|---|---|
ABE-12-8071-50 | 50 µg | - |
3 - 11 business days* |
819.00€
|
If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk
Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable... more
Product information "Anti-IL 12/23 (Briakinumab) - APC (human)"
Expression Host : HEK-293 This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Keywords: | Anti-IL12B, Anti-NKSF2, Anti-IL-12B, Anti-CLMF p40, Anti-IL-12 subunit p40, Anti-Interleukin-12 subunit beta, Anti-NK cell stimulatory factor chain 2, Anti-Cytotoxic lymphocyte maturation factor 40 kDa subunit |
Supplier: | Abeomics |
Supplier-Nr: | 12-8071 |
Properties
Application: | FA |
Antibody Type: | Monoclonal |
Clone: | ABT-874 |
Conjugate: | APC |
Host: | Human |
Species reactivity: | human |
Database Information
KEGG ID : | K05425 | Matching products |
UniProt ID : | P29460 | Matching products |
Gene ID | GeneID 3593 | Matching products |
Handling & Safety
Storage: | +4°C |
Shipping: | +4°C (International: °C) |
Caution
Our products are for laboratory research use only: Not for administration to humans!
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow.
more
You will get a certificate here
Viewed